Cardinal Health vs Cvs Health
CAH and CVS side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAH and CVS compare
Cvs Health is the larger company, worth 2.0 times as much as Cardinal Health ($115B against $58.3B).
On earnings, Cvs Health is cheaper: it trades at 23.9× trailing earnings, against 34.6× for Cardinal Health.
Cardinal Health grew revenue faster over the last twelve months (14.2% versus 7.4% for Cvs Health).
Cvs Health keeps more of each dollar of sales as profit, with a net margin of 1.2% compared with 0.67% at Cardinal Health.
Both pay dividends: Cardinal Health yields 0.82% and Cvs Health 2.2%.
Cardinal Health scores higher on the StockData Score (16 against 12 for Cvs Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAH | CVS |
|---|---|---|
| Size and price | ||
| Market cap | $58.3B | $115B |
| Share price | $250.48 | $90.25 |
| Change, 1 year | 52.3% | 12.0% |
| Change, 5 years | 406% | −3.8% |
| Beta (5Y) | 0.47 | 0.47 |
| Employees | 64K | 300K |
| StockData Score | ||
| Total score | 16 (better) | 12 |
| Valuation score | 1 | 1 |
| Growth score | 4 (better) | 3 |
| Performance score | 4 (better) | 2 |
| Health score | 3 (better) | 2 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 34.6× | 23.9× (better) |
| P/S | 0.2× (better) | 0.3× |
| P/B | – | 1.4× |
| EV/EBITDA | 17.5× | 12.7× (better) |
| P/FCF | 12.9× | 9.8× (better) |
| PEG | 0.44 | – |
| FCF yield | 7.8% | 10.2% (better) |
| Fair value | $196.59 | $77.92 |
| Margin of safety | −27.4% | −15.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 14.2% (better) | 7.4% |
| Revenue growth, 5Y average | 9.4% (better) | 8.4% |
| Net income growth (TTM) | 9.8% (better) | 7.9% |
| EPS growth (TTM) | 12.1% (better) | 5.3% |
| EPS growth, 5Y average | 28.3% (better) | −23.9% |
| Profitability | ||
| Gross margin | 3.8% | 44.5% (better) |
| Operating margin | 1.0% | 2.0% (better) |
| Net margin | 0.67% | 1.2% (better) |
| FCF margin | 1.8% | 2.8% (better) |
| Return on equity | – | 6.2% |
| Return on invested capital | 136% (better) | 5.5% |
| Financial health | ||
| Debt / equity | – | 0.77 |
| Net debt / EBITDA | 1.13 (better) | 3.70 |
| Interest coverage | 7.5× (better) | 2.7× |
| Current ratio | 0.88 (better) | 0.87 |
| Altman Z-score | 5.11 (better) | 2.45 |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.82% | 2.2% (better) |
| Payout ratio | 28.6% | 69.9% |
| Years of dividend growth | 17 (better) | 0 |
| Dividend growth, 5Y average | 1.0% | 5.9% (better) |
| Buyback yield | 2.3% | – |
| Shareholder yield | 3.2% (better) | 2.2% |
| Ownership | ||
| Held by institutions | 88.7% | 89.2% |
| Held by insiders | 0.28% | 0.43% |
| Insider net buying, 12 months | −$61.6M (better) | −$324M |
| Superinvestors holding | 2 | 6 (better) |
| Short interest, % of float | 3.2% | 1.3% |
Go deeper
- CAH stock overview
- CAH income statement
- CAH valuation and score
- CVS stock overview
- CVS income statement
- CVS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.